Dr. Stephen H. Dyar JR., MD

Medicare patients and services

Medicare patients, 2024

576

Services billed

1,144

Patients’ average age

75

Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.

Medicare prescriptions

Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.

Payments from drug and device companies

In 2025, 3 companies reported 36 payments worth $53,989 in total to this clinician.

What the payments were for

Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.

From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.

Who received the most in South Carolina →

Industry-funded research

Named as a principal investigator on 20 industry-funded studies in 2025, from 11 companies. The companies reported $968,327 in research payments for these studies, mostly to the institutions running them.

• A Phase II Multicenter, Open-label, Single-arm Dose Escalation Study of Asciminib Monotherapy in 2nd Line Chronic Phase - Chronic Myelogenous Leukemia
  Novartis Pharmaceuticals Corporation
• A phase 1B2 openlabel study of disitamab vedotin in combination with other anticancer therapies in solid tumors
  Pfizer Inc.
• A Phase 3, Randomized, Open-label Study to Evaluate Perioperative Enfortumab Vedotin Plus Pembrolizumab MK-3475 Versus Neoadjuvant Gemcitabine and Cisplatin in Cisplatin-eligible Participants with Muscle-invasive Blad…
  Merck Sharp & Dohme LLC
• A Phase 3 Open-label Trial of Neoadjuvant Trastuzumab Deruxtecan (T-DXd) Monotherapy or T-DXd followed by THP Compared to ddAC-THP in Participants with High-risk HER2-positive Early-stage Breast Cancer (DESTINY-Breast11)
  AstraZeneca Pharmaceuticals LP
• Capivasertib plus Palbociclib plus Fulvestrant for HR/HER2 Advanced Breast Cancer CAPItello 292.
  AstraZeneca Pharmaceuticals LP
• A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)
  Regeneron Pharmaceuticals, Inc. · Recruiting · NCT06246916
• A Phase III, Randomised, Open-Label, Multicentre Study of Datopotamab Deruxtecan or Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer Without Actionable Geno…
  AstraZeneca Pharmaceuticals LP
• A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer
  Eli Lilly and Company · Active, not recruiting · NCT05514054
• IMCODE004
  Genentech, Inc.
• A Study of Relatlimab Plus Nivolumab in Combination With Chemotherapy vs. Nivolumab in Combination With Chemotherapy as First Line Treatment for Participants With Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)
  E.r. Squibb & Sons, L.l.c. · Completed · NCT04623775

From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.

Other Hematology & Oncology clinicians in Greenville

• Britt H. Bolemon, M.D.
• Reginald J. Brooker, MD
• Saeeda Z. Chowdhury, M.D.
• Elizabeth H. Cull, M.D.
• Suzanne R. Fanning, D.O.
• William L. Gluck, MD
• Kim O. Gococo, MD
• Joanna Grabska, MD